85 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
RVNC Revance Therapeutics, Inc. $23.5001 $868.04M N/A
Article Searches
Botox Durability Is The Key Value Driver For Allergan https://seekingalpha.com/article/4247699-botox-durability-key-value-driver-allergan?source=feed_sector_healthcare Mar 11, 2019 - Allergan’s recent failure with Rapastinel adds to the company’s woes. However, there is a portion of the investor community that remains believers in Allergan’s underlying value.These investors see va
Revance Therapeutics Inc (RVNC) Files 10-K for the Fiscal Year Ended on December 31, 2018 http://www.gurufocus.com/news/825801/revance-therapeutics-inc-rvnc-files-10k-for-the-fiscal-year-ended-on-december-31-2018 Mar 01, 2019 - Revance Therapeutics Inc (RVNC) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: RVNC, release date:Mar 01, 2019
Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4244522-revance-therapeutics-inc-rvnc-ceo-daniel-browne-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 26, 2019 - Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communi
Revance Therapeutics Inc (RVNC) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/26/revance-therapeutics-inc-rvnc-q4-2018-earnings-con.aspx?source=iedfolrf0000001 Feb 26, 2019 - RVNC earnings call for the period ending December 31, 2018.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines http://www.zacks.com/stock/news/352006/allergan-stock-falls-as-fda-oks-botox-rival-for-frown-lines?cid=CS-ZC-FT-352006 Feb 05, 2019 - Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Biocept leads healthcare gainers; Achieve Life Sciences and Revance Therapeutics among losers https://seekingalpha.com/news/3423527-biocept-leads-healthcare-gainers-achieve-life-sciences-revance-therapeutics-among-losers?source=feed_news_all Jan 16, 2019 -
Revance Therapeutics: New Data And Partnership A Welcome Development https://seekingalpha.com/article/4226447-revance-therapeutics-new-data-partnership-welcome-development?source=feed_sector_healthcare Dec 05, 2018 - Shares have risen by just 5% since my initial article and lost a quarter of their value since my last update.I provide a recap of the bullish thesis and recent events.SAKURA phase 3 open-label data wa
Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4217445-revance-therapeutics-inc-rvnc-ceo-daniel-browne-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Nov 01, 2018 - Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2018 Earnings Conference Call November 1, 2018, 16:30 ET Executives Jeanie Herbert - Senior Director of IR & Corporate Communications Daniel Browne - Co
Revance Therapeutics: A New Contender In The Botox Arena https://seekingalpha.com/article/4205300-revance-therapeutics-new-contender-botox-arena?source=feed_sector_healthcare Sep 10, 2018 - Revance is a clinical-stage biotechnology company focused on the development and commercialization of botulinum toxin (Botox) products for cosmetic and therapeutic applications.Near-term catalysts inc
Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy? http://www.zacks.com/stock/news/311720/revance-therapeutics-sees-hammer-chart-pattern-time-to-buy?cid=CS-ZC-FT-311720 Jul 17, 2018 - Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Pages: 123456...9

Page 1>

Related Companies

Name Exchange Price Mkt Cap
ASMB Assembly Biosciences, Inc. NASDAQ $34.41 $875.61M
RCKT Rocket Pharmaceuticals, Inc. NASDAQ $22.24 $882.06M
AMPH Amphastar Pharmaceuticals, Inc. NASDAQ $18.33 $847.88M
AMRN Amarin Corporation plc NASDAQ $2.83 $838.67M
CTMX CytomX Therapeutics, Inc. NASDAQ $18.52 $832.73M
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Revance Therapeutics
RVNC - Google Finance https://www.google.com/finance?q=RVNC Industry related info and international coverage Summary News
RVNC - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=RVNC Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options